FDA Approves IMULDOSA (ustekinumab-srlf), Accord BioPharma's Biosimilar to STELARA (ustekinumab), for the Treatment of Chronic Inflammatory Conditions
PRNewswire Ahmedabad Gujarat [India] October 14 Accord BioPharma Inc the US specialty division of Intas Pharmaceuticals Ltd ...
Drug Store News8d
Accord BioPharma receives FDA OK for 420 mg strength of Hercessi
The 420 mg strength of Hercessi, a biosimilar to Herceptin, is used to treat HER2-overexpressing breast and gastric or ...
Managed Healthcare Executive2d
FDA Approves Imuldosa, the Fifth Stelara Biosimilar
Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.
devdiscourse3d
FDA Greenlights IMULDOSA: A Game-Changer in Biosimilar Treatments
Accord BioPharma has received FDA approval for IMULDOSA, a biosimilar to STELARA, for treating chronic inflammatory conditions like psoriasis and Crohn's disease. Scheduled for a 2025 launch, it aims ...
centerforbiosimilars13d
Eye on Pharma: High-Strength Trastuzumab Biosimilar; Originator Coverage Removals; CHMP Aflibercept Opinion
The FDA approved a new strength of a trastuzumab biosimilar; UnitedHealth will remove reference adalimumab from some ...
Fox 5 San Diego3d
Nile basin nations say water-sharing accord has come into force without Egypt’s backing
Ethiopia, Uganda, Rwanda, Burundi and Tanzania have ratified the accord. Egypt and Sudan declined to sign, while Congo abstained. Kenya has not yet deposited its ratification documents with the ...
Newsday2d
Nile basin nations say water-sharing accord has come into force without Egypt's backing
Ethiopia, Uganda, Rwanda, Burundi and Tanzania have ratified the accord. Egypt and Sudan declined to sign, while Congo abstained. Kenya has not yet deposited its ratification documents with the ...